In This Section      
 

Search Results

A total of 20 matching records were found.

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J11120
A phase II trial of low dose fractionated radiation therapy as a chemo-potentiator of salvage temozolomide for recurrent anaplastic astrocytoma and glioblastoma multiforme

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J12106
A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High-risk Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1426
“A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1444
The feasibility and biologic effect of a modified Atkins-based intermittent fasting diet in patients with high-grade astrocytoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15214
A Pilot Study of Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16138
Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Metastatic Chordoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17154
Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination with Anti-PD-1 (Nivolumab) in Patients with First Recurrence of Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17181
A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain from Bone Metastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1737
Preservation of Cognition and Neuropsychiatric Functioning with Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1745
A pilot study to assess safety and feasibility of 5 fraction hypofractionated stereotactic radiosurgery (treating tumor and edema) along with standard temozolomide for newly diagnosed glioblastoma, including assessment of lymphocyte sparing effect.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital

J1801
A Pilot Study to evaluate the pharmacokinetic, pharmacodynamic, and resistance profile to trametinib and dabrafenib in BRAF-V600E mutated recurrent gliomas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1840
Radiation Immunodynamics: The Immune Response to Standard Therapy in Patients with Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1202
Phase I Study of AZD1775 (adavosertib) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1403
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA0577
N0577 CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

PAPEC1621I
APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore